Cardinal Health, Inc. is a global healthcare company specializing in the distribution of pharmaceuticals and medical products, playing a critical role in connecting manufacturers with providers and patients within the Healthcare sector's Medical Distribution industry. The company's operations are segmented into Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution, offering a wide array of services and supplies. In its most recent reported quarters, Cardinal Health demonstrated a positive earnings trend, with Q3 2025 EPS at $2.55, an increase from Q2 2025's $2.08, Q1 2025's $2.35, and Q4 2024's $1.93. Revenue also showed an upward trajectory, reaching $64.01 billion in Q3 2025, up from $60.16 billion in Q2 2025, $54.88 billion in Q1 2025, and $55.26 billion in Q4 2024, indicating a general acceleration in both earnings and revenue growth over this period. The company has consistently beaten analyst EPS estimates in the last four reported quarters, showcasing a strong performance against expectations. Looking at its historical performance, Cardinal Health has exhibited a generally positive year-over-year growth trajectory in its earnings. Notable beats against analyst estimates have been a recurring theme, reinforcing its ability to exceed market expectations. The consistent pattern of revenue growth, often accompanied by EPS beats, highlights the company's operational strength. Recent news indicates Cardinal Health is significantly expanding its Actinium-225 production capacity, a key component for advanced cancer therapies, which could bolster its role in next-generation drug development and potentially impact future revenue streams. This expansion, coupled with an upward revision of full-year EPS guidance, signals strong financial momentum. Investors should watch for further updates on the commercialization of these therapies and their impact on CAH's revenue and profitability in upcoming quarters, as well as continued positive earnings surprises against analyst estimates.
